Balance Sheet
Accounts PayablesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityConstruction in ProgressCurrent AssetsCurrent TaxesGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxLong-Term InvestmentsMinority InterestNon-Current AssetsNon-Current DebtNon-Current Deferred Tax LiabilityNotes PayablesOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Dr Reddys Laboratories (RDY) Other Non-Current Liabilities (2018 - 2025)

Historic Other Non-Current Liabilities for Dr Reddys Laboratories (RDY) over the last 14 years, with Q4 2025 value amounting to $427.0 million.

  • Dr Reddys Laboratories' Other Non-Current Liabilities changed N/A to $427.0 million in Q4 2025 from the same period last year, while for Dec 2025 it was $427.0 million, marking a year-over-year change of. This contributed to the annual value of $39.0 million for FY2025, which is 1875.0% down from last year.
  • Latest data reveals that Dr Reddys Laboratories reported Other Non-Current Liabilities of $427.0 million as of Q4 2025.
  • Dr Reddys Laboratories' Other Non-Current Liabilities' 5-year high stood at $427.0 million during Q4 2025, with a 5-year trough of $382.65 in Q2 2022.
  • Its 5-year average for Other Non-Current Liabilities is $222.8 million, with a median of $323.9 million in 2021.
  • Per our database at Business Quant, Dr Reddys Laboratories' Other Non-Current Liabilities plummeted by 9999.99% in 2022 and then surged by 10053907315.89% in 2023.
  • Dr Reddys Laboratories' Other Non-Current Liabilities (Quarter) stood at $325.0 million in 2021, then rose by 6.0% to $344.5 million in 2022, then grew by 8.52% to $373.8 million in 2023, then tumbled by 80.76% to $71.9 million in 2024, then surged by 493.8% to $427.0 million in 2025.
  • Its last three reported values are $427.0 million in Q4 2025, $27.0 million for Q3 2025, and $426.3 million during Q1 2025.